February 12, 2018 / 11:34 AM / 10 months ago

BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA

Feb 12 (Reuters) - Contravir Pharmaceuticals Inc:

* CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXL™ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY

* CONTRAVIR PHARMACEUTICALS - FDA ALLOWS CO TO USE 505(B)(2) REGULATORY PATHWAY TO STREAMLINE DEVELOPMENT & REGISTRATION OF TXL FOR TREATING CHRONIC HEPATITIS B Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below